Morning chemo could add months to glioblastoma patient survival

Giving chemotherapy in the morning rather than the evening could add a few months to patient survival, a new study shows.
Glioblastoma is an aggressive type of brain cancer with no cure. Patients survive an average of 15 months after diagnosis, with fewer than 10% of patients surviving longer than five years.
Average overall survival for all patients in the study, which appears in
Neuro-Oncology Advances, was about 15 months after diagnosis. Those receiving the chemotherapy drug temozolomide in the morning had an average overall survival of about 17 months post diagnosis, compared with an average overall survival of about 13½ months for those taking the drug in the evening, a statistically significant difference of about 3½ months.

Related Keywords

Annar Damato ,Joshuab Rubin ,Jianl Campian ,Erikd Herzog , ,Siteman Cancer Center Biostatistics Shared Resource ,Brain Tumor Center At Siteman ,Siteman Cancer Center At Barnes ,Louis School Of Medicine ,Washington University School Of Medicine ,Washington University In St ,Neuro Oncology Advances ,Washington University ,Louis School ,Siteman Cancer Center ,Barnes Jewish Hospital ,Washington University School ,Brain Tumor Center ,Siteman Cancer Center Biostatistics Shared ,அன்னார் டமாட்டோ ,லூயிஸ் பள்ளி ஆஃப் மருந்து ,வாஷிங்டன் பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து ,வாஷிங்டன் பல்கலைக்கழகம் இல் ஸ்டம்ப் ,வாஷிங்டன் பல்கலைக்கழகம் ,லூயிஸ் பள்ளி ,களஞ்சியங்கள் நகை மருத்துவமனை ,வாஷிங்டன் பல்கலைக்கழகம் பள்ளி ,மூளை கட்டி மையம் ,